Oragenics Inc (OGEN)
0.364
-0.01
(-2.15%)
USD |
NYAM |
Nov 12, 16:00
0.34
-0.02
(-6.59%)
After-Hours: 20:00
Oragenics Research and Development Expense (Quarterly): 0.9068M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.9068M |
| March 31, 2024 | 0.6634M |
| December 31, 2023 | 11.04M |
| September 30, 2023 | 0.7693M |
| June 30, 2023 | 2.007M |
| March 31, 2023 | 1.673M |
| December 31, 2022 | 1.412M |
| September 30, 2022 | 2.777M |
| June 30, 2022 | 2.59M |
| March 31, 2022 | 3.294M |
| December 31, 2021 | 1.310M |
| September 30, 2021 | 3.547M |
| June 30, 2021 | 2.468M |
| March 31, 2021 | 3.261M |
| December 31, 2020 | 3.352M |
| September 30, 2020 | 3.498M |
| June 30, 2020 | 11.54M |
| March 31, 2020 | 3.713M |
| December 31, 2019 | 2.760M |
| September 30, 2019 | 3.068M |
| June 30, 2019 | 3.879M |
| March 31, 2019 | 2.414M |
| December 31, 2018 | 1.794M |
| September 30, 2018 | 1.580M |
| June 30, 2018 | 1.272M |
| Date | Value |
|---|---|
| March 31, 2018 | 1.326M |
| December 31, 2017 | 0.8153M |
| September 30, 2017 | 0.9965M |
| June 30, 2017 | 0.6054M |
| March 31, 2017 | 1.122M |
| December 31, 2016 | 1.776M |
| September 30, 2016 | 0.9248M |
| June 30, 2016 | 0.7927M |
| March 31, 2016 | 1.225M |
| December 31, 2015 | 1.341M |
| September 30, 2015 | 1.104M |
| June 30, 2015 | 5.612M |
| March 31, 2015 | 0.6766M |
| December 31, 2014 | 0.5482M |
| September 30, 2014 | 0.597M |
| June 30, 2014 | 0.9033M |
| March 31, 2014 | 1.016M |
| December 31, 2013 | 1.069M |
| September 30, 2013 | 6.907M |
| June 30, 2013 | 0.637M |
| March 31, 2013 | 0.7454M |
| December 31, 2012 | 0.7302M |
| September 30, 2012 | 0.6002M |
| June 30, 2012 | 6.177M |
| March 31, 2012 | 0.3532M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.6634M
Minimum
Mar 2024
11.54M
Maximum
Jun 2020
3.294M
Average
2.760M
Median
Dec 2019
Research and Development Expense (Quarterly) Benchmarks
| Shuttle Pharmaceuticals Holdings Inc | 0.6457M |
| Perspective Therapeutics Inc | 9.275M |
| Alaunos Therapeutics Inc | 0.18M |
| Cocrystal Pharma Inc | 4.308M |
| Cara Therapeutics Inc | 9.308M |